| Adalimumab maintains Crohn's disease remission; the subcutaneously injected drug is currently approved by the FDA for the treatment of arthritis.(Digestive ... An article from: Family Practice News | Digitalby Mitchel L. Zoler (Author)
| List Price: | $5.95 | | | Available: | Available for download now |
| | Binding: | Digital | | Publisher: | Thomson Gale | | Page Count: | 3 Pages | | Publication Date: | December 15, 2005 |
|
EDITORIAL REVIEWS |
Product Description
This digital document is an article from Family Practice News, published by Thomson Gale on December 15, 2005. The length of the article is 691 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Adalimumab maintains Crohn's disease remission; the subcutaneously injected drug is currently approved by the FDA for the treatment of arthritis.(Digestive Disorders)Author: Mitchel L. ZolerPublication: Family Practice News (Magazine/Journal)Date: December 15, 2005Publisher: Thomson GaleVolume: 35 Issue: 24 Page: 46(1)Distributed by Thomson Gale |
|
